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Abstract 
Background: S100A13 and high mobility group A (HMGA1) are known to play essential roles in the carcinogenesis 
and progression of cancer. However, the correlation between S100A13 and HMGA1 during cancer progression is not 
yet well understood. In this study, we determined the effects of S100A13 on HMGA1 expression in thyroid cancer cells 
and examined the role of HMGA1 in thyroid cancer progression.
Methods: Stable ectopic S100A13 expression TT cellular proliferation was evaluated by nude mice xenografts assays. 
The effect of lentivirus‑mediated S100A13 knockdown on thyroid cancer cellular oncogenic properties were evalu‑
ated by MTT, colony formation assays and transwell assays in TPC1 and SW579 cells. The effect of siRNA‑mediated 
HMGA1 knockdown on thyroid cancer cellular proliferation and invasion were evaluated by MTT, colony formation 
assays and transwell assays. The tissue microarray was performed to investigate the correlation between S100A13 and 
HMGA1 expression in tumor tissues.
Results: The ectopic expression of S100A13 could increase tumor growth in a TT cell xenograft mouse model. Moreover, 
lentivirus‑mediated S100A13 knockdown led to the inhibition of cellular oncogenic properties in thyroid cancer cells, 
and HMGA1 was found to be involved in the effect of S100A13 on thyroid cancer growth and invasion. Furthermore, 
siRNA‑mediated HMGA1 knockdown was proved to inhibit the growth of TPC1 cells and invasive abilities of SW579 
cells. Clinically, it was revealed that both S100A13 and HMGA1 showed a higher expression levels in thyroid cancer 
cases compared with those in matched normal thyroid cases (P = 0.007 and P = 0.000); S100A13 and HMGA1 expres‑
sions were identified to be positively correlated (P = 0.004, R = 0.316) when analyzed regardless of thyroid cancer 
types.
Conclusions: This is the first report for the association between HMGA1 and S100A13 expression in the modulation 
of thyroid cancer growth and invasion. Those results would provide an essential insight into the effect of S100A13 
on carcinogenesis of thyroid tumor, rending S100A13 to be potential biological marker for the diagnosis of thyroid 
cancer.
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Background
S100A13 is a small calcium (Ca2+)-binding protein 
which belongs to the S100 family. It is characterized by 
its specificity for diverse forms of cancer [1–3]. S100A13 
could regulate secretion of FGF1 and IL1α and could be a 
marker for vessel density and on a cellular level [4, 5]. In 
addition S100A13 is also involved in cell cycle progres-
sion and differentiation, including cytokine and NF-κB 
signalling, suggesting that S100A13 may be related to 
increased aggressiveness of melanoma tumours [6, 7]. 
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the elevated expression of S100A13 and risk of relapse 
and status of melanoma patients at follow-up, indicating 
that S100A13 may play a crucial role in melanoma chem-
oresistance [8, 9]. Moreover, S100A13 was found to be 
involved in the invasiveness of lung cancer cell lines [10], 
and also was detected in tumor cells circulating in blood 
of patients with metastatic cancer [11], indicating that 
this protein may be considered as a predictor of cancer 
metastases. Recently, a study on cystic papillary thyroid 
carcimoma (cPTC) confirmed a significant up-regulation 
of cytokeratin 19 and S100A13 in cPTC compared to 
benign lesions, suggesting their possible use in fine nee-
dle aspiration biopsy based preoperative diagnostics of 
cystic thyroid lesions [12]. With multiplexed and targeted 
mass spectrometry method, S100A13 was also found to 
be elevated in papillary thyroid carcinoma (PTC) com-
pared to normal tissue, suggesting that S100A13 may be 
considered as a novel candidate PTC biomarker [13].
High mobility group A (HMGA1) is an architectural 
transcription factor that encodes a nonhistone chroma-
tin protein. Two isoforms, HMGA1a and HMGA1b are 
produced which do not show direct transcriptional reg-
ulation activities, but they regulate the transcriptional 
activity of several genes by altering the chromatin struc-
ture [14–16]. The expression of HMGA1 is absent or 
present only at low level in normal cell and adult tissues 
but are elevated in embryonic cells [17] and many malig-
nant neoplasias, including breast [18], pancreas [19], lung 
[20], ovary [21], colon [22] and thyroid carcinomas [23]. 
HMGA1 has been confirmed to associate with the initia-
tion and progression of diverse types of tumors [24–27]. 
HMGA1 has also been reported to correlate with the 
presence of metastasis and reduced survival [28], and 
could be a poor prognostic marker.
In this study, we examined the effects of S100A13 and 
HMGA1 on thyroid cancer progression. The results sug-
gest that HMGA1 was involved in the effect of S100A13 
on thyroid cancer growth and invasion by modulating 
the expression of Snail and E-cadherin. In addition, a tis-
sue microarray revealed that higher expressions of both 
S100A13 and HMGA1 were observed in thyroid cancer 
cases compared with that in normal thyroid cases. Statis-
tical analysis also confirmed that S100A13 and HMGA1 
expressions were positively correlated. This study estab-
lish the first link between S100A13 and HMGA1 in thy-
roid cancer, providing further evidence of the pivotal role 
of HMGA1 in thyroid cancer progression.
Methods
Cell culture
Human thyroid cancer cell line TT, TPC1 and SW579 
were purchased from American Type Culture Collection 
(USA). After thawing, TT cells were cultured in F12  K 
(N3520; Sigma, USA) medium supplemented with 10  % 
fetal bovine serum (Gibco, USA) and NaHCO3 2.5 g/L at 
37  °C in a humidified atmosphere containing 5  % CO2. 
TPC1 cells were cultured in DMEM medium supple-
mented with 10 % fetal bovine serum at 37 °C in a humid-
ified atmosphere containing 5 % CO2. SW579 cells were 
cultured in L15 medium supplemented with 10  % fetal 
bovine serum at 37 °C in a humidified atmosphere with-
out CO2. After three passages, cells were used for viral 
infection.
Western blot analysis
Total cell lysates were lysed on ice for 30  min. Solu-
ble proteins (20  μg) were probed with anti-S100A13, 
anti-HMGA1, anti-Snail, and anti-E-cadherin antibod-
ies (1:500, Abcam). Loading variations were normalized 
against β-actin, which was identified by anti-β-actin 
monoclonal antibody (1:1000, Abcam).
Construction and screening of lentiviral vectors harboring 
S100A13‑specific siRNA
The siRNA sequences targeting to human S100A13 
gene (GenBank accession No. NM_001024210) were 
selected: Target1: ATGAGTACTGGAGATTGAT; Tar-
get2: CTCGGAGCTCAAGTTCAAT; and Target3: 
TGGGCTCTCTTGATGAGAA. Three pairs of com-
plementary oligonucleotides were then designed (Addi-
tional file  1: Table S1). The stem-loop oligonucleotides 
were synthesized and cloned into a lentivirus-based vec-
tor carrying the green fluorescent protein (GFP) gene 
(pGCSIL-GFP, Genechem, Shanghai, China). A universal 
sequence (PSC-NC: TTCTCCGAACGTGTCACGT) was 
used as a negative control for RNA interference. Lentivi-
ral particles were prepared as previously described [29].
Three siRNA-carrying lentiviral vector constructs were 
used to infect TPC1 at a multiplicity of infection (MOI) 
of 20 (low MOI) and 40 (high MOI). Three days after 
infection, GFP expression was detected to calculate the 
infection efficiency. Five days after infection, cells were 
harvested. Real-time reverse transcription polymerase 
chain reaction (RT-PCR) was performed to determine 
S100A13 knockdown efficiency and screen for the siRNA 
with the highest knockdown efficiency which was then 
used for subsequent experiments.
RNA isolation and reverse transcription PCR (RT‑PCR)
The SW579 were treated with Scramble RNA or HMGA1 
siRNA (40, 80, 160  nM), and maintained in culture 
medium for 48  h. Total RNA was extracted from the 
SW579 cells using TRIzol reagent (Invitrogen) and the 
total RNA was reverse transcribed into cDNA using the 
first-strand synthesis kit (Gibco-BRL, Carlsbad, CA, 
USA). The mRNAs of HMGA1, E-cadherin, Snail and 
Page 3 of 13Zhong et al. J Transl Med  (2016) 14:80 
β-actin were amplified using the primers (Additional 
file 2: Table S2). The gene-specific primers were amplified 
with a denaturation step (95 °C for 2 min), followed by 35 
cycles of denaturation (95  °C for 30 s), annealing (55  °C 
for 30  s) and extension (72  °C for 50  s). Samples from 
three separate experiments were analyzed in duplicate. 
The results from RT-PCR were expressed using β-actin as 
a reference.
Cell proliferation and colony formation assays
For cell proliferation assays, cells were seeded in a 96-well 
plate (2000 cells/well) and counted using an automated 
cell counter (Nexcelom Bioscience, Lawrence, MA, USA). 
For colony formation assay, cells were seeded in a 12-well 
plate (400 cells/well) and maintained for 8  days. Each 
experiment was carried out in triplicate and performed 
at least twice.
Cell invasion assays
For the invasion assays, 10,000 cells were resuspended in 
serum-free medium and placed in the upper chamber of 
a 24-well Matrigel™ Invasion Chamber (BD Biosciences, 
SanDiego, CA, USA) coated with Matrigel. Cell inva-
sion was calculated as the percentage of total cells that 
had invaded the bottom chamber containing complete 
medium with serum.
Scratch‑wound assays
For the scratch-wound assays, cells were transiently 
transfected with shRNA vectors and grown to conflu-
ence. A central linear wound area was carefully cre-
ated by scraping the cell monolayer with a sterile 200 μl 
pipette tip, and images were taken after 24 h. Bars repre-
sent as the mean percentage of wound closure relative to 
the initial wound area.
Tumour xenografts
Four-week-old BALB/c female nude mice were fed on the 
super-clean biological laminar flow shelf for 1 week. All 
of the in  vivo experimental protocols were approved by 
the Animal Care Committee of South China University. 
The details of tumour xenografts assay were performed 
as described previously [30].
Transient transfection and luciferase activity assay
Transient gene delivery was carried out to assess the 
effect of HMGA1 on Snail and E-cadherin promoter 
activity in SW579 cells as described previously [31]. A 
luciferase assay kit (Promega) was used to measure the 
reporter activity according to the manufacturer’s instruc-
tions. Luciferase activity was normalized by using a 
Renilla luciferase internal control.
Tissue microarray and immunohistochemical analysis
The tissue microarray (TH8010, US Biomax) consisting 
70 thyroid cancer cases and 10 normal cases was utilized, 
and was histologically interpretable and analyzed for the 
correlation with clinicopathological parameters. IHC 
staining was performed as detailed in our previous stud-
ies [30]. The mouse monoclonal S100A13 (1:25; ab55701, 
Abcam) antibody and the rabbit polyclonal HMGA1 anti-
body (1:150; ab4078, Abcam) were used.
Statistical analysis
All experiments were performed with three replicates 
and the results were expressed as the mean ± S.E.M or 
mean  ±  SD. Statistical analysis was done using SPSS, 
version 13.0. A statistical association between clinico-
pathological and molecular parameters was tested, using 
non-parametrically two-tailed Mann–Whitney U test. 
P values  <  0.05 were considered significant. Spearman’s 
rank-correlation coefficients were used to assess the rela-
tionship between S100A13 and HMGA1 expression.
Results
S100A13 overexpression increases tumor growth in a TT 
cell xenograft mouse model
It was previously revealed that S100A13 had essential 
roles in various cancer, we therefore exploited whether 
S100A13 was involved in the development of thyroid can-
cer. Using Stable cell lines with the GFP and S100A13-GFP, 
we found that overexpression of S100A13 in the trans-
fected thyroid cancer TT cells markedly increased cells 
proliferate ability, and decreased population percentage of 
G0/G1 period compared to those cells with either GFP or 
untransfected TT cells [32]. To further examine the effects 
of S100A13 on cell proliferation in  vivo, we transplanted 
three types of thyroid tumours cells developed from TT 
cells (S100A13-GFP, GFP and TT) into nude mice. Growth 
of the implanted tumours was measured in mice (n =  5 
for each group) over a period of 7 weeks. Overexpression 
of S100A13 dramatically increased the size and weight of 
tumors compared to those engrafted with GFP cells or 
with untransfected TT cells (P < 0.05 and P < 0.01, Fig. 1a, 
b), but the difference between the GFP cells group and 
untransfected TT cells group was not significant. Cyclin E, 
one of the key gene of cell cycle was found to be upregu-
lated in S100A13-GFP cells (Fig.  1c), indicating that it 
might be involved in S100A13 induced cell proliferation. 
HMGA1, an architectural transcription factor associat-
ing with the initiation and progression of diverse types of 
tumors, also was found to be upregulated in S100A13-GFP 
cells (Fig.  1c). Those data suggest that overexpression of 
S100A13 enhances oncogenic properties of thyroid cancer 
cells in vitro and in vivo.
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Fig. 1 S100A13 overexpression increases tumor growth in a TT cell xenograft mouse model. a S100A13‑GFP, GFP or TT groups cells were trans‑
planted into ovariectomized athymic mice. Left mice appearances in different treated groups. Right tumor appearances in different treated groups. 
b Left increased tumor volume in S100A13 overexpression mice. Tumours were measured weekly using a vernier calliper and the volume was calcu‑
lated according to the formula: π/6 × length × width2. Each point represents the mean ± SD for different animal measurements (n = 5) (*P < 0.05). 
Right increased tumor weight in S100A13 overexpression mice (**P < 0.01). c Detection of proteins expression by immunohistochemical assay of 
tumor tissues in nude mice in different treated groups (streptavidin biotin complex ×400)
Page 5 of 13Zhong et al. J Transl Med  (2016) 14:80 
S100A13 knockdown inhibits in vitro cell growth in the 
least/non‑invasive cell line
S100A13/GV248RNAi-LV-1 was transfected into thy-
roid cancer TPC1 cells and SW579 cells, individually. 
The infection efficiencies of these lentiviral vectors were 
all above 90  % as revealed by fluorescence microscopy 
(Fig. 2a, b). Real-time RT-PCR assay showed that all three 
constructs, whether they were used at a high or low MOI, 
could significantly downregulate S100A13 gene expres-
sion in TPC1 cells (Additional file 3: Figure S1). As shown 
in Fig. 3a, the MTT assay showed that TPC1 cell prolif-
eration was significantly inhibited in the S100A13 knock-
down group as compared to those of the control group 
and the NC group at the fifth days (P  <  0.05), however, 
Fig. 2 a Fluorescence microscopy examination of the infection efficiencies of different lentiviral vectors in TPC1 cells (magnification ×100). I, TPC1 
cells without lentiviral infection (Con group) in the light microscope; II, TPC1 cells of Con group in the fluorescence microscope; III, TPC1 cells were 
infected with negative lentivirus NC/GV248RNAi‑LV (NC group) in the light microscope; IV, TPC1 cells of NC group in the fluorescence microscope; V, 
TPC1 cells were infected with lentivirus S100A13/GV248RNAi‑LV#1 RNAi (KD group) at a high MOI in the light microscope; VI, TPC1 cells of KD group 
at a high MOI in the fluorescence microscope. b Fluorescence microscopy examination of the infection efficiencies of different lentiviral vectors in 
SW579 cells (magnification ×100). The description of panels was similar with that in a
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Fig. 3 Lentivirus‑mediated S100A13 knockdown inhibited thyroid cancer cell proliferation and invasion. a Growth curves of cells in each group. 
MTT analysis showed that lentivirus‑mediated S100A13 knockdown significantly inhibited thyroid cancer TPC1 cell proliferation (n = 3). *P < 0.05. 
b Colony formation assay showed that lentivirus‑mediated S100A13 knockdown significantly inhibited thyroid cancer TPC1 cell colony formation 
(n = 3, **P < 0.01). c Transwell invasion assay showed that lentivirus‑mediated S100A13 knockdown significantly inhibited thyroid cancer SW579 
cell invasion. Cells were transiently transfected with lentivirus‑mediated shRNA plasmids and plated on the top of the transwells. Twenty‑four hours 
after plating, cells invaded through the pores were counted. Values are expressed as mean ± SD of three independent experiments, *P < 0.05. d 
Scratch-wound assay showed that lentivirus‑mediated S100A13 knockdown significantly inhibited thyroid cancer SW579 cell migration. e Western 
blot assay showed that lentivirus‑mediated S100A13 knockdown inhibited expression of HMGA1 and Snail, promoted expression of E‑cadherin in 
SW579 cells
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the SW579 cell proliferate ability of S100A13 knockdown 
group showed no significant difference compared to 
those of the control group and the NC group at the indi-
cated time points (Additional file 4: Figure S2a). 
Colony formation assay showed that the number of 
formed colonies from TPC1 cells with lentivirus-medi-
ated S100A13 knockdown was markedly decreased com-
pared to those of the control group and the NC group 
(Fig. 3b, P < 0.01). Whereas, the number of formed colo-
nies of SW579 cells carrying with lentivirus-mediated 
S100A13 knockdown showed no significant difference 
to those of the control group and NC group (Additional 
file 4: Figure S2b). Those results indicated that S100A13 
knockdown could inhibit the cell proliferation and colony 
formation of the least/non-invasive thyroid cancer TPC1 
cells, but show no obvious effect on the proliferate ability 
of invasive thyroid cancer SW579 cells.
S100A13 knockdown inhibits the invasive and migration 
capabilities through decrease the expression of HMGA1 
in thyroid cancer SW579 cells
To determine if S100A13 knockdown was able to affect 
the invasion properties of thyroid cancer TPC1 cells and 
SW579 cells, the transwell invasion assay and scratch-
wound assay were performed. As shown in Fig.  3c, com-
pared to those of the control group and the NC group, 
the invasion rate of SW579 cells in the S100A13 knock-
down group decreased significantly (P  < 0.05). As well as 
the result of invasion assay, the migration capability of the 
S100A13 knockdown group decreased significantly com-
pared to those of the control group and the NC group 
(Fig. 3d, P < 0.01). The invasive and migration capabilities 
showed no significant difference between the control group 
and the NC group (Fig.  3c, d). The thyroid cancer TPC1 
cells, however, showed no invasive capability even in the 
control group, and the migration capability of TPC1 cell 
with the S100A13 knockdown group showed no obvious 
difference compared to those of the NC group (Additional 
file 5: Figure S3). To determine if S100A13 knockdown was 
able to affect the expressions of invasion associated fac-
tors, the western blot was performed. As shown in Fig. 3e, 
S100A13 knockdown could lead to the downregulation of 
HMGA1 and Snail and the upregulation of E-cadherin in 
SW579 cells. Moreover, the ectopic S100A13 expression 
could increase both HMGA1 and Snail mRNA expressions 
(Additional file  6: Figure S4) and enhance the promoter 
activities (Additional file 7: Figure S5).
HMGA1 knockdown inhibits in vitro cell growth 
and invasion
It was reported that HMGA1 overexpression could pro-
mote the growth and invasion of cancer cells [24–27]. To 
address the effect of HMGA1 on thyroid cancer cells, the 
HMGA1 targeting siRNA were used. As shown in Fig. 4a 
and b, HMGA1 silence in TPC-1 cell could inhibit the 
cell proliferation and decrease the colony formation abil-
ity. Furthermore, it was revealed that the siRNA induced 
HMGA1 could lead to the downregulation of Snail and 
upregulation of E-cadherin in both mRNA or protein lev-
els in SW579 cells (Fig. 4c), resulting in the decrease of 
invasive abilities of thyroid cancer SW579 cells (Fig. 4d, 
P < 0.01).
To further clarify the mechanism by which HMGA1 
affect the expression of Snail or E-cadherin in SW579 
cells, luciferase reporter assay was performed. It was 
demonstrated that HMGA1 could enhance the promoter 
activities of Snail gene and inhibit the promoter activi-
ties of E-cadherin in a dose-dependent manner (Fig. 5a, 
b). Those results indicate that HMGA1 might affect the 
expression of E-cadherin and Snail by regulating the pro-
moters’ activities in SW579 cells.
S100A13 correlates with HMGA1 expression in thyroid 
carcinoma
To further indentify the relationship between S100A13 
and HMGA1 expression in thyroid cancer, tissue micro-
array (TH8010, US Biomax), consisting of 70 thyroid 
cancer cases and 10 normal cases was used, and the clin-
icopathologic data were available in Table 1. The immu-
nohistochemistry analysis showed that S100A13 was 
stained in 94.3  % of thyroid tumors, predominantly in 
nuclear with faint cytoplasmic staining, and was stained 
in 60.0 % in normal thyroid tissue (P = 0.007, Table 2). 
HMGA1 was stained in 98.6  % of thyroid tumors, pre-
dominantly in nuclear with faint cytoplasmic stain-
ing, and was stained in 60.0  % in normal thyroid tissue 
(P  =  0.000, Table  2). S100A13 and HMGA1 immu-
nostainings of tumor and normal tissue of representative 
cases of thyroid carcinoma are shown in Fig. 6. Further-
more, S100A13 and HMGA1 expressions were found 
to be positively correlated (r = 0.316, P = 0.004), when 
analyzed regardless of thyroid cancer types (Table  3). 
S100A13 expressions in thyroid carcinoma did not show 
a statistically significant correlation with patient age and 
nodal metastasis of the tumor (Table 1, P > 0.05). How-
ever, S100A13 expression in thyroid carcinoma was 
shown to be more common in male than that in female, 
and much higher in papillary cancer compared with 
follicular cancer and undifferentiated cancer (Table  1, 
P = 0.049 and 0.051). HMGA1 expression in thyroid car-
cinoma also showed a statistically significant correlation 
with the patient sex and tumor types (Table 1, P = 0.016 
and 0.003). Those tissue microarray data confirmed that 
S100A13 and HMGA1 expression were positively corre-
lated in thyroid carcinoma, and it may be involved in the 
progression of thyroid cancer.  
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Discussion
The S100 protein family has been implicated in the reg-
ulation of a number of cellular processes such as cell 
growth and differentiation, cell cycle progression, phos-
phorylation regulation of proteins, protein secretion, 
organization of membrane structure and cytoskeleton 
dynamics [33]. Recently, increasing number of studies 
report that S100 family members are associated with a 
variety of human diseases, including neurodegenera-
tion, inflammatory disorders and cancers [34]. In par-
ticular, S100A4, S100A6, S100A7 and S100A10 have 
been found to be overexpressed in some cancer types, 
Fig. 4 SiRNA‑mediated HMGA1 knockdown inhibited thyroid cancer cell proliferation and invasion. a Growth curves of cells in each group. 
MTT analysis showed that siRNA‑mediated HMGA1 knockdown significantly inhibited thyroid cancer TPC1 cell proliferation (n = 3). *P < 0.05. b 
Colony formation assay showed that siRNA‑mediated HMGA1 knockdown significantly inhibited thyroid cancer TPC1 cell colony formation (n = 3, 
**P < 0.01). c RT‑PCR and western blot assay showed that siRNA‑mediated HMGA1 knockdown inhibited mRNA and protein expression of HMGA1 
and Snail, promoted mRNA and protein expression of E‑cadherin in thyroid cancer SW579 cell. d Transwell invasion assay showed that siRNA‑medi‑
ated HMGA1 knockdown significantly inhibited thyroid cancer SW579 cell invasion. Cells were transiently transfected with HMGA1‑siRNA and plated 
on the top of the transwells. Twenty‑four hours after plating, cells invaded through the pores were counted. Values are expressed as mean ± SD of 
three independent experiments, **P < 0.01
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and could be associated with aggressive cancer pheno-
type [35–39]. However, the molecular mechanisms of 
S100 proteins implicating in tumor progression remain 
to be elucidated. S100A13 is the member of S100 family, 
and it has been shown to be involved in the nonclassical 
export of signal-peptideless proteins, including fibroblast 
Fig. 5 HMGA1 overexpression affect Snail and E‑candherin promoter activities in SW579 cell. a, b Luciferase activity assay showed that HMGA1 
overexpression inhibited promoter activity of E‑cadherin, promoted promoter activity of Snail in a dose‑dependent manner
Table 1 Correlation of S100A13 and HMGA1 expression with clinicopathological parameters
n S100A13 P value HMGA1 P value
− + ++ +++ − + ++
Age (years) 0.549 0.984
 >50 30 2 7 20 1 0 13 17
 ≤50 40 2 7 30 1 1 16 23
Sex 0.049 0.016
 Male 14 0 1 12 1 0 2 12
 Female 56 4 13 38 1 1 27 28
Tumor types 0.051 0.003
 Papillary 46 2 5 38 1 1 14 31
 Follicular 18 1 7 9 1 0 14 4
 Undifferentiated 6 1 2 3 0 0 1 5
Node metastasis 0.213 0.063
 Positive 17 0 2 15 0 0 4 13
 Negative 53 4 12 35 2 1 25 27
Table 2 Expressions of S100A13 and HMGA1 in thyroid normal tissue and cancer
n S100A13 P value HMGA1 P value
Positive Negative Positive Negative
Tissue types 0.007 0.000
 Normal 10 6 4 6 4
 Tumor 70 66 4 69 1
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growth factors, interleukin 1α, and synaptotagmins 
[40, 41]. Recent data showed that S100A13 is related to 
inflammatory functions [5]. It was also reported that 
S100A13 expressed differentially during brain develop-
ment, suggesting that it may play a role in nervous system 
function [41–43]. Increasing evidences also showed the 
Table 3 Correlation of S100A13 and HMGA1 expression
n HMGA1 Spearman (r) P value
− + ++
S100A13 0.316 0.004
 − 4 1 2 1
 + 14 0 6 8
 ++ ~ +++ 52 0 21 31





Fig. 6 S100A13 and HMGA1 protein expression show a positive correlation in thyroid carcinoma (images in original magnification, ×200). a Normal 
thyroid tissue, b thyroid papillary carcinoma, c thyroid follicular carcinoma, d thyroid undifferentiated carcinoma
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association between S100A13 and tumourigenesis, indi-
cating the role of S100A13 in initial and progression in 
diversity of cancer [6, 7, 9–11].
In this study, experiments were performed to determine 
the effects of S100A13 on cell proliferation, and we dem-
onstrated that the ectopic expression of S100A13 could 
enhance cellular proliferation of thyroid cancer TT cells 
in vivo. To further define the effect of S100A13 on other 
thyroid cancer cells, three lentivirus-mediated S100A13 
gene targeting shRNA (KD1, KD2 and KD3) were used to 
silence the expression of S100A13 in thyroid cancer TPC1 
and SW579 cells. It was revealed that the downregulation 
of S100A13 could inhibit the TPC1 cells growth in  vitro 
and lead to the decrease of invasive and migration ability of 
SW579 cell line in vitro. Those findings provide evidences 
for the involvement of S100A13 in the modulation of thy-
roid cancer cell proliferation and invasion. It was reported 
that the IL1α-S100A13 complex plays an important role in 
cell proliferation and angiogenesis, and would be an effec-
tive strategy to inhibit a wide range of cancers [41]. It was 
also reported that S100A13 increased in human astrocytic 
gliomas, in which it correlates with VEGF-A expression, 
microvessel density and tumor grading [7] and it is also 
associated with a more aggressive, invasive phenotype in 
lung cancer-derived cell lines [10]. Moreover, S100A13 
was detected in tumor cells circulating in blood of patients 
with metastatic cancer, indicating that S100A13 could be 
considered as a predictor of metastases [11].
Intriguingly, the siRNA induced S100A13 downre-
gualtion was found to cause the decreased expression of 
HMGA1 and Snail and increased E-cadherin expression 
in SW579 cells, indicating the involvements of HMGA1, 
Snail and E-cadherin in S100A13 induced celluar pro-
liferation and invasion. Recent study reports silencing 
HMGA1 could block proliferation, migration and inva-
sion of triple negative breast cancer MDA-MB-231 cells. 
Mesenchymal genes (Vimentin, Snail) are repressed, 
while E-cadherin is induced in the HMGA1 knock-down 
cells [18]. In our study, the downregulation of HMGA1 
was further confirmed to be able to decrease and increase 
the expression of Snail and E-cadherin respectively, 
resulting in the suppression of TPC1 cells proliferation 
and SW579 cells invasion. Those results indicate that 
S100A13 and HMGA1 show the consisitent effects on the 
proliferation and invasion of thyroid cancer cells.
The higher expressions of both S100A13 and HMGA1 
were observed in thyroid cancer tissues compared with 
that in normal thyroid tissues through the analysis of tis-
sue microarray, indicating that the elevated expression 
of S100A13 and HMGA1 in thyroid cancer tissue might 
play a role in the initiation and progression of thyroid 
cancer. Further analysis to the tissue microarray data 
unraveled a positive correlation between S100A13 and 
HMGA1 expression (P  =  0.004) regardless of thyroid 
cancer types, which is consistent with the results from 
cells models, suggesting that S100A13 may be of impor-
tance in regulating HMGA1 expression in human thyroid 
cancer, and that S100A13 might be responsible for the 
increased ability of proliferation and invasion in thyroid 
cancer cells. Moreover, the expressions of S100A13 and 
HMGA1 in thyroid carcinoma were shown to be associ-
ated with the patient sex and tumor types, which is not 
be reported in other cancers previously. The further clari-
fication of underlying molecular events would be helpful 
for understanding the role of S100A13 and HMGA1 in 
the progression of thyroid cancer.
Conclusions
In summary, this is the first report for the association 
between HMGA1 and S100A13 expression in the mod-
ulation of thyroid cancer growth and invasion. Those 
results would provide an essential insight into the effect 
of S100A13 on carcinogenesis of thyroid tumor, rending 
S100A13 to be potential biological marker for the diag-
nosis of thyroid cancer.
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